フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024 Programme PBC (sous...
PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024Launch of Iqirvo® (elafibranor)1 on track...
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024 PBC program (licensed to Ipsen): Ipsen to present new...
GENFIT : Information financière du troisième trimestre 2024 Trésorerie et équivalents de trésorerie s’élevant à 96,0 millions d’euros au 30...
Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in revenues for the nine months ended September 30, 2024...
GENFIT Reports Third Quarter 2024 Financial Information Cash and cash equivalents totaled €96.0 million as of September 30, 2024€59.7 million in...
GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA...
GENFIT : Iqirvo® d’Ipsen (elafibranor) reçoit l’approbation UE en tant que traitement first-in-class de la Cholangite Biliaire Primitive...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 23, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a...
GENFIT : Résultats financiers du premier semestre 2024 et point sur les activités de la Société Trésorerie et équivalents de trésorerie s’élevant...
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update Cash and cash equivalents totaled €61.6 million as of June...
Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in...
GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis Lille (France), Cambridge...
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage...
GENFIT : Avis positif du Comité des médicaments à usage humain (CHMP) pour l’Iqirvo® (élafibranor) d’Ipsen dans la Cholangite Biliaire Primitive...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約